IPO - ARCH Venture Fund IX, L.P.

Form Type: CORRESP

Filing Date: 2025-02-24

Corporate Action: Ipo

Type: Update

Accession Number: 000110465925016578

Filing Summary: This letter addresses comments from the SEC regarding the late filing of a Schedule 13D for Boundless Bio, Inc. by ARCH Venture Fund IX, L.P. The Schedule 13D was necessitated by ARCH's acquisition of more than 5% of Boundless shares following an IPO on April 2, 2024, where ARCH purchased 200,000 shares at $16 each. A clerical error led to the misunderstanding of required filing obligations, as ARCH believed its acquisition timing was compliant with the 12-month rule. This letter outlines the corrective measures ARCH is implementing to ensure timely future filings and confirms that no additional shares have been acquired since the IPO.

Document Link: View Document